VIDEO: Bevy of psoriasis data at AAD 2026 promises more to come

DENVER — In this video, Joseph F. Merola, MD, MMSc, FAAD, discusses important psoriasis data presented at the American Academy of Dermatology Annual Meeting.
Some psoriasis presentations of note included new data on recently FDA-approved icotrokinra (Icotyde, Johnson & Johnson), next-generation tyrosine kinase inhibitors izasocitinib (Takeda) and envudeucitinib (Alumis Inc.), combination therapy with ixekizumab (Taltz, Eli Lilly) and tirzepatide (Zepbound, Eli Lilly) and results from the TOGETHER-PsO study.
“There was a lot to be excited about and to pick apart in psoriasis at

Pooled analysis reveals semaglutide shows good efficacy in older adults aged over 65 years

A new analysis of the STEP trials carried out by semaglutide manufacturer Novo Nordisk has analyzed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations. The study is by Prof Luca Busetto from the University of Padova in Italy and colleagues, including those from Novo Nordisk.

Not just insulin: Early increases in glucagon in type 2 diabetes are linked to fatty liver disease

Until now, research into type 2 diabetes has focused primarily on insulin: if the body's cells become less responsive to the hormone produced in the pancreas, blood glucose levels rise over the long term. A recent study by the German Diabetes Center now shows that levels of the hormone glucagon are also elevated at an early stage. The paper is published in the journal Diabetes Care.